Related Experiment Video
Updated: Jul 15, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
N6-methyladenosine RNA modification in nonalcoholic fatty liver disease
Ping Luo1, Shiqi Li2, Wei Jing3
1Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, influencing numerous regulatory axes and extrahepatic vital organs. The molecular mechanisms that lead to the progression of NAFLD remain unclear and knowledge on the pathways causing hepatocellular damage followed by lipid accumulation is limited. Recently, a number of studies have shown that mRNA N6-methyladenosine (m6A) modification contributes to the progression of NAFLD. In this review, we summarize current knowledge on m6A modification in the metabolic processes associated with NAFLD and discuss the challenges of and prospects for therapeutic avenues based on m6A regulation for the treatment of liver disease.
Insights
Nonalcoholic fatty liver disease (NAFLD) involves complex molecular pathways. This review explores how mRNA N6-methyladenosine (m6A) modification impacts NAFLD progression and discusses potential m6A-targeted therapies.
Area of Science:
- Hepatology
- Molecular Biology
- Metabolic Diseases
Background:
- Nonalcoholic fatty liver disease (NAFLD) is a prevalent global liver condition.
- The precise molecular mechanisms driving NAFLD progression and hepatocellular damage are not fully understood.
- Emerging research implicates mRNA N6-methyladenosine (m6A) modification in NAFLD pathogenesis.
Purpose of the Study:
- To review current understanding of m6A modification in NAFLD.
- To elucidate the role of m6A in metabolic processes relevant to NAFLD.
- To explore therapeutic strategies targeting m6A regulation for liver disease treatment.
Main Methods:
- Literature review of studies on m6A modification and NAFLD.
- Analysis of m6A's involvement in metabolic pathways.
- Discussion of current and future therapeutic prospects.
Main Results:
- m6A modification is increasingly recognized as a key factor in NAFLD progression.
- m6A influences various metabolic processes contributing to liver damage and lipid accumulation.
- Specific m6A regulators show potential as therapeutic targets.
Conclusions:
- m6A modification plays a significant role in the development and progression of NAFLD.
- Targeting m6A pathways offers promising therapeutic avenues for treating liver disease.
- Further research is needed to fully harness m6A-based treatments for NAFLD.
Related Concept Videos
RNA Editing
RNA Stability
Pre-mRNA Processing: Modification of pre-mRNA Ends
Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps...
Nuclear Export of mRNA

